Merck & Co., Inc. (NYSE:MRK) Position Lessened by Harel Insurance Investments & Financial Services Ltd.

Harel Insurance Investments & Financial Services Ltd. trimmed its position in shares of Merck & Co., Inc. (NYSE:MRK) by 60.4% in the 3rd quarter, Holdings Channel.com reports. The fund owned 3,877 shares of the company’s stock after selling 5,919 shares during the quarter. Harel Insurance Investments & Financial Services Ltd.’s holdings in Merck & Co., Inc. were worth $326,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the stock. NumerixS Investment Technologies Inc increased its position in Merck & Co., Inc. by 138.7% during the second quarter. NumerixS Investment Technologies Inc now owns 32,468 shares of the company’s stock worth $2,722,000 after buying an additional 18,868 shares during the last quarter. Girard Partners LTD. increased its position in Merck & Co., Inc. by 2.7% during the second quarter. Girard Partners LTD. now owns 103,298 shares of the company’s stock worth $8,661,000 after buying an additional 2,720 shares during the last quarter. Alps Advisors Inc. increased its position in Merck & Co., Inc. by 15.9% during the second quarter. Alps Advisors Inc. now owns 38,470 shares of the company’s stock worth $3,226,000 after buying an additional 5,273 shares during the last quarter. Lowe Wealth Advisors LLC increased its position in Merck & Co., Inc. by 12.0% during the second quarter. Lowe Wealth Advisors LLC now owns 1,396 shares of the company’s stock worth $117,000 after buying an additional 150 shares during the last quarter. Finally, Bartlett & Co. LLC increased its position in Merck & Co., Inc. by 7.0% during the second quarter. Bartlett & Co. LLC now owns 96,074 shares of the company’s stock worth $8,056,000 after buying an additional 6,271 shares during the last quarter. Institutional investors and hedge funds own 74.64% of the company’s stock.

MRK has been the topic of several analyst reports. Credit Suisse Group reissued a “buy” rating and set a $95.00 target price on shares of Merck & Co., Inc. in a research report on Wednesday, August 7th. Deutsche Bank reaffirmed a “neutral” rating and issued a $104.00 price target on shares of Merck & Co., Inc. in a research report on Tuesday. Argus raised their price target on Merck & Co., Inc. to $105.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Morgan Stanley reaffirmed a “buy” rating on shares of Merck & Co., Inc. in a research report on Wednesday. Finally, ValuEngine downgraded Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and thirteen have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $95.06.

MRK stock traded up $0.75 during trading on Wednesday, reaching $84.87. 3,993,704 shares of the stock were exchanged, compared to its average volume of 10,067,262. Merck & Co., Inc. has a twelve month low of $70.89 and a twelve month high of $87.35. The company has a market capitalization of $212.82 billion, a P/E ratio of 19.56, a price-to-earnings-growth ratio of 1.81 and a beta of 0.54. The stock has a 50 day simple moving average of $83.93 and a 200-day simple moving average of $82.92. The company has a current ratio of 1.26, a quick ratio of 0.98 and a debt-to-equity ratio of 0.84.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, October 29th. The company reported $1.51 earnings per share for the quarter, topping analysts’ consensus estimates of $1.24 by $0.27. Merck & Co., Inc. had a return on equity of 48.16% and a net margin of 20.26%. The business had revenue of $12.40 billion for the quarter, compared to the consensus estimate of $11.59 billion. During the same period last year, the business earned $1.19 earnings per share. The firm’s revenue for the quarter was up 14.9% compared to the same quarter last year. Equities analysts predict that Merck & Co., Inc. will post 5.16 EPS for the current year.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Recommended Story: How Do Tariffs Affect Trade Balances?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.